Smarter Discovery
Dynamic Precision
Real-World Patient Data:
We learn from real-world cancer patients to understand why many of them do not respond when treated with today’s standard of care therapy. This enables us to identify targets for tomorrow’s new therapies that will benefit these patients.
Functional Validation:
We confirm that each new therapeutic target has a functional role in inhibiting response to the current standard of care, and by understanding the biology of the new target, we will be smarter in designing and developing new therapies for patients.
Blood-based biomarker:
We know that every patient is different. So we learn from real-world patient insights to develop blood-based markers to identify which patients are likely to benefit from new therapies. This improves the overall success probability and shortens the timeline to a successful drug.
Real-World Patient Data:
We learn from real-world cancer patients to understand why many of them do not respond when treated with today’s standard of care therapy. This enables us to identify targets for tomorrow’s new therapies that will benefit these patients.
Functional Validation:
We confirm that each new therapeutic target has a functional role in inhibiting response to the current standard of care, and by understanding the biology of the new target, we will be smarter in designing and developing new therapies for patients.
Blood-based biomarker:
We know that every patient is different. So we learn from real-world patient insights to develop blood-based markers to identify which patients are likely to benefit from new therapies. This improves the overall success probability and shortens the timeline to a successful drug.
